Aiming to understand the roles played by p53 mutants in promoting tumor progression and in chemotherapy failure, we studied EMT and CSC populations pursuant to various treatments in cancer cells heterozygously carrying a p53 missense mutation, in cell culture and in tumor-bearing mice. This evidence concerns the gene TP53 and neoplasm.